From: Alltop RSS
Respond to this topic on your own blog
Click and press Ctrl+C to copy and paste this discussion on your blog or site
Related Articles
Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
SUMMARY: Asian-American and white patients with genotype 1 or 2/3
chronic hepatitis C have a similar likelihood of achieving
sustained response to pegylated interferon plus ribavirin,
according to a California study described in the May 2010 American
Journal of Gastroenterology. Investigators suggested that seemingly
higher Asian response rates seen in previous studies were due to
misclassifying easier-to-treat HCV genotype 6 as genotype 1. By Liz
Highleyman It is well known that race/ethnicity influences response
to interferon-based combination therapy for chronic hepatitis C
virus (HCV) infection. Numerous studies have shown that people of
African descent -- and possibly Hispanics/Latinos, though data less
inconsistent -- do not respond as well as Caucasians; some research
has f...
Response at Week 8 Accurately Predicts Sustained Response to Pegylated Interferon plus Ribavirin for Hepatitis C
SUMMARY: Virological response to interferon-based therapy at week 8
is as likely to accurately predict which chronic hepatitis C
patients will go on achieve sustained response as the usual 12-week
stopping algorithm, according to a study published in the May 2010
Journal of Viral Hepatitis. Using this earlier cut-off for
treatment discontinuation could spare patients the side effects and
cost of additional futile therapy. l By Liz Highleyman lEarly
virological response (EVR) -- an HCV viral load decline of at least
2 logs 12 weeks after starting pegylated interferon plus ribavirin
-- is typically used as a "stopping rule" to predict which
hepatitis C patients are likely to achieve sustained virological
response (SVR) as measured 24 weeks after completing treatment.
Individuals who ...
e-newsletter can be viewed online by clicking here
SUMMARY: Longer treatment with antiviral agents such as lamivudine,
and use of pegylated interferon for selected individuals, increases
the likelihood of sustained hepatitis B "e" antigen seroconversion
and viral suppression in people with chronic hepatitis B, according
to a set of recently published reports.
Telaprevir or Boceprevir/SVR Rates/According To Genotypes/2010
Hi Folks, Exciting news, today Merck’s announced
their Phase III trials for boceprevir have been completed. k In
both studies : . (treatment-failure; HCV RESPOND-2) and their
(treatment-naïve; HCV SPRINT-2) study . Patients with
genotype 1 significantly increased sustained virologic response
(SVR; defined as undetectable virus levels 24 weeks after the end
of treatment), compared to control groups, (Which ARE the group)=
that received NO Boceprevir but only "Peg/riba plus placebo." , I
have put together the SVR stats treating HCV according to genotype
with "Telaprevir and Boceprevir"/ in combination with Pegylated
interferon and Ribavirin. With using the current limited data
available thus far. Please make sure you click on the links
associated with ...
Theophylline improves steroid sensitivity in acute alcoholic hepatitis.
Related Articles Theophylline improves steroid sensitivity in acute
alcoholic hepatitis. Hepatology. 2010 Jul;52(1):126-31 Authors:
Kendrick SF, Henderson E, Palmer J, Jones DE, Day CP Corticosteroid
therapy has shown some benefit in severe acute alcoholic hepatitis
(AAH); however, this is limited by uncertainty in patient selection
and variable clinical response. Theophylline has been shown to
ameliorate impaired steroid sensitivity in chronic obstructive
pulmonary disease by facilitating corticosteroid-induced silencing
of proinflammatory genes. We aimed to explore the mechanistic basis
of the variable response to ...